TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22336721
Drug: Glutamate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (0.5 mol/L) injection into the masseter muscle
Study: 22336721
Drug: Co-injection of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-injection of ketamine (20 mmol/L) with glutamate
Study: 17872679
Drug: Single-dose intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intrathecal narcotics (ITN) with a combination of 2.5 mg of bupivacaine, 25 microg of fentanyl, and 250 microg of morphine.
Study: 3513528
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg guanfacine
Study: 3513528
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg guanfacine
Study: 9766253
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test at room temperature (0.1 U per kg of BW, i.v.)
Study: 9766253
Drug: Insulin tolerance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin tolerance test under increased ambient temperature for 45 min before and after insulin injection
Study: 26686957
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg per day
Study: 24452393
Drug: TAS-114 single
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-114 single dose (6, 18, 60, 150, and 300 mg)
Study: 24452393
Drug: TAS-114 multiple
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-114 multiple doses (14 days consecutively)
Study: 18683218
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg monthly for 1 year)
Study: 9293855
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (FLU) as salvage chemotherapy, 25 mg/m2 for 5 consecutive days, repeated every 28 days for a maximum of 6 cycles.
Study: 9293855
Drug: Alpha-interferon (alpha-IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon (alpha-IFN) maintenance therapy, 3x10^6 units 3 times per week until disease progression.
Study: 9293855
Drug: Alpha-interferon (alpha-IFN)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon (alpha-IFN) maintenance therapy vs no further therapy after FLU response.
Study: 9332921
Drug: Diltiazem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.1 mg/kg per h)
Study: 2783492
Drug: Acupuncture‐like TENS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture‐like TENS treatment (10-minute treatment bilaterally to five acupuncture points on the auricle)
Study: 21806694
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo pill)
Study: 31783028
Drug: 2% Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Vitamin C solution (VCS)
Study: 31783028
Drug: 5% Sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Sodium thiosulfate solution (STS)
Study: 17055858
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (NS)
Study: 30641692
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (7 viable strains: Lactobacillus, Bifidobacterium, and Streptococcus) for 6 weeks
Study: 25515658
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) at a dosage of 30 Gy in 10 fractions
Study: 21332742
Drug: 1% citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% citric acid solution (pH 2.3) for 20 minutes
Study: 16789982
Drug: ASA and
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA and Codeine combination
Study: 7954555
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous isosorbide dinitrate
Study: 30019829
Drug: Buccal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal approach (control group)
Study: 25500887
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) 2.5 mg/kg intravenously followed by pegylated G-CSF 6 mg subcutaneously every 2 weeks for 6 doses
Study: 25500887
Drug: Anti-thymocyte globulin
Normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thymocyte globulin (ATG) and pegylated G-CSF
Study: 21395446
Drug: Weekly Fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Fast Facts and Concept (FFAC) e‐mails, 32 e‐mails over 32 weeks
Study: 21395446
Drug: Weekly Fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Fast Facts and Concept (FFAC) e‐mails
Study: 17190104
Drug: 4G-beta-D-galactosylsucrose (lactosucrose;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4G-beta-D-galactosylsucrose (lactosucrose; LS) 6.0 g twice daily
Study: 17190104
Drug: Placebo (maltose;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltose; 6.0 g twice daily)
Study: 14707396
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg once daily (o.d.)
Study: 14707396
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 microg twice daily (b.i.d.)
Study: 16817839
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg o.d.
Study: 9444014
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg single dose
Study: 10023867
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 0.5 mg/kg/day
Study: 10023867
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1.0 mg/kg/day
Study: 10023867
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 2.0 mg/kg/day
Study: 10023867
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) (any dose)
Study: 401759
Drug: Trental 400
Normalized name: Trental 400mg Extended-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental 400 (400 mg Pentoxifylline per tablet), 3 tablets daily for 3 months
Study: 401759
Drug: Comparative formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative formulation (2.4 mg adenosine per tablet), 3 tablets daily for 3 months
Study: 31969713
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% spray, 1-2 applications (0.1-0.2 ml) for 8 weeks, containing 5-10 mg of lidocaine
Study: 31969713
Drug: Placebo (alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (alcohol 40% spray), 1-2 applications (0.1-0.2 ml) for 8 weeks
Study: 28546852
Drug: Resveratrol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1000 mg/day for 28 days)
Study: 23532686
Drug: ASA+ER‐DP 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA+ER‐DP 25 mg/200 mg BID alone (Treatment A)
Study: 23532686
Drug: ASA+ER‐DP 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA+ER‐DP 25 mg/200 mg BID + omeprazole 80 mg QD (Treatment B)
Study: 23532686
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg QD alone (Treatment C)
Study: 23532686
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg QD + ASA+ER‐DP 25 mg/200 mg BID (Treatment D)
Study: 19071979
Drug: Take‐home methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take‐home methadone doses contingent on cocaine‐ and opiate‐negative results (THM)
Study: 19071979
Drug: Take‐home methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take‐home methadone doses for cocaine‐ and opiate‐negative results and monetary‐based vouchers contingent on cocaine‐negative urinalysis results (THM + V)
Study: 12817520
Drug: Etoricoxib (5-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (5-500 mg single doses and 25-150 mg multiple doses)
Study: 12817520
Drug: Etoricoxib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (up to 150 mg qd)
Study: 11165311
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate administration
Study: 6516935
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy without imagery (RET)
Study: 6516935
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy with imagery (REI)
Study: 6516935
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy (RET) and Rational-emotive therapy with imagery (REI)
Study: 29765212
Drug: Conjugated Linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Linoleic Acid (CLA) supplement, 3.2 g daily for 6 weeks
Study: 29765212
Drug: Placebo, 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3.2 g daily for 6 weeks
Study: 27189289
Drug: AST-120 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (6 g/day) for 6 months
Study: 23607203
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy (including pre‐ and postoperative irradiation, surgery, adjuvant chemotherapy)
Study: 23607203
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with adjuvant chemotherapy
Study: 20105041
Drug: P1+ (preserved
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1+ (preserved first-phase insulin secretion)
Study: 20105041
Drug: P1- (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1- (no first-phase insulin secretion)
Study: 16257791
Drug: 3 months'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months' androgen deprivation (3.6 mg goserelin subcutaneously every month and 250 mg flutamide orally three times a day)
Study: 9633847
Drug: Multiple cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple cycles of high-dose chemotherapy with hematopoietic support (colony-stimulating factors and peripheral blood progenitor cells)
Study: 9633847
Drug: Multiple cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple cycles of high-dose chemotherapy
Study: 7493828
Drug: Conformal brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal brachytherapy (CB) with HDR boost implants (5.5 Gy, 6 Gy, 6.5 Gy)
Study: 7493828
Drug: Interactive online
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive online planning system for HDR treatment
Study: 6127890
Drug: Prenalterol 20‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol 20‐200 mg daily (slow‐release tablet preparation)
Study: 27254743
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU daily)
Study: 27254743
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU daily) + Calcium (1200 mg daily)
Study: 27603424
Drug: BCG monotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG monotherapy (Connaught 120 mg, 6 weekly instillations followed by 10 instillations)
Study: 27603424
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with mitomycin C (MMC 40 mg, 6 weekly instillations followed by 10 instillations of BCG)
Study: 15214141
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation (400 ml, 400 kcal) daily for six months
Study: 15214141
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 ml) daily for six months
Study: 12720592
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplementation
Study: 9619529
Drug: Intra-nasal buserelin
Normalized name: buserelin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal buserelin (doses ranged from a single 25 microg dose to 100 microg every 4 h for 20 h)
Study: 7655763
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g piracetam i.v. (250 ml infusion over 30 minutes)
Study: 7655763
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g piracetam p.o. (60 ml sirup)
Study: 2073165
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg OD
Study: 6772199
Drug: Propranolol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (320 mg total)
Study: 6772199
Drug: Metoprolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (400 mg total)
Study: 28523589
Drug: Alternating acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating acetaminophen and ibuprofen (acetaminophen 10 mg/kg per dose with shortest interval of 4 h and ibuprofen 10 mg/kg per dose with shortest interval of 6 h; n=158)
Study: 28523589
Drug: Acetaminophen monotherapy
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen monotherapy (10 mg/kg per dose with shortest interval of 4 h; n=158)
Study: 28523589
Drug: Ibuprofen monotherapy
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen monotherapy (10 mg/kg per dose with shortest interval of 6 h; n=158)
Study: 23789747
Drug: Postoperative PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative PCA with tramadol (20 mg) and metoclopramide (1 mg) per bolus
Study: 23789747
Drug: Postoperative PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative PCA with morphine (1 mg) per bolus
Study: 8666599
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (Control)
Study: 14990013
Drug: Rabeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Clarithromycin (500 mg twice daily) for 1 week (RAC group)
Study: 14990013
Drug: Rabeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (10 mg twice daily) + Amoxicillin (1000 mg twice daily) + Metronidazole (400 mg twice daily) for 1 week (RAM group)
Study: 9877365
Drug: Immunoglobulins extracted
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulins extracted from immunized bovine colostrum (IIBC) 10 g daily for 4 days
Study: 9877365
Drug: Placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation (10 g daily for 4 days)
Study: 30770745
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of resection, post-operative SRS/SFRT and SRS/SFRT to intact lesions
Study: 27617368
Drug: Already prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Already prescribed a respiratory medication
Study: 23910581
Drug: Nesiritide therapy
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide therapy (0.006 μg kg(‐1) min(‐1))
Study: 17412329
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein supplement
Study: 15118618
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg ethinyl estradiol + 100 microg levonorgestrel followed by 7 pill-free days
Study: 15118618
Drug: 7-day pill-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day pill-free interval
Study: 11310514
Drug: Oral syringe
Normalized name: Oral Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral syringe
Study: 9141918
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Study: 9141918
Drug: Right atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right atrial administration of epinephrine at 100 ng.kg‐1.min‐1
Study: 7894222
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) and Unfractionated heparin
Study: 3690032
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg almitrine
Study: 27028316
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg spray
Study: 16796150
Drug: Fish-oil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil (4 g/day)
Study: 16796150
Drug: Soy-oil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-oil (4 g/day)
Study: 10799796
Drug: Postoperative pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain medications before educational program
Study: 10799796
Drug: Postoperative pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative pain medications after educational program
Study: 10799796
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of acute postoperative pain medication
Study: 8638023
Drug: EP-guided antiarrhythmic
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-guided antiarrhythmic drug therapy (propafenone, flecainide, disopyramide, sotalol, amiodarone)
Study: 1597023
Drug: E5 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 2.5 mg/kg
Study: 1597023
Drug: E5 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5 7.5 mg/kg
Study: 30314856
Drug: ACTI-BREAK intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTI-BREAK intervention (3×5min active breaks incorporated into classroom routine daily)
Study: 24697278
Drug: Controlled-release cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release cilostazol formulation
Study: 24697278
Drug: Pletal (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pletal (twice-daily immediate-release formulation)
Study: 20400005
Drug: Propofol 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.3 mg/kg
Study: 20400005
Drug: Propofol 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.6 mg/kg
Study: 20400005
Drug: Propofol 2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.3 mg/kg
Study: 16377698
Drug: BAL8557 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (100 mg of BAL4815)
Study: 16377698
Drug: BAL8557 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (200 mg of BAL4815)
Study: 16377698
Drug: BAL8557 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (400 mg of BAL4815)
Study: 16377698
Drug: BAL8557 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL8557 (50 mg of BAL4815)
Study: 10808172
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg with loratadine 10 mg
Study: 8673937
Drug: Ketorolac oral
Normalized name: ketorolac Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac oral 10 mg at six hour intervals for 24 hours
Study: 8673937
Drug: Ketorolac injectable
Normalized name: ketorolac Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac injectable 10 mg at the height/depth of the buccal vestibule of the tooth to be treated
Study: 8673937
Drug: No assigned
Approvals — FDA: no, EMA: no, PMDA: no
Description: No assigned medication (control group)
Study: 1633067
Drug: Frusemide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 60 mg as two oral controlled release (CR) formulations
Study: 1633067
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets of Frusemide 60 mg
Study: 6094278
Drug: Ketoconazole in
Normalized name: Product containing ketoconazole in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole in combination with chemical nail avulsion (group B)
Study: 31250992
Drug: RPh201 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 (5 mg, 10 mg, 20 mg) in SAD stage
Study: 31250992
Drug: RPh201 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 (5 mg, 10 mg, 20 mg) in MAD stage
Study: 21821621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical items indicative of inflammatory back pain for diagnosing axial spondyloarthritis (SpA)
Study: 21821621
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical items indicative of inflammatory back pain
Study: 11289194
Drug: Gatifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 600 mg
Study: 11289194
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg and 600 mg, Ofloxacin 400 mg
Study: 3606238
Drug: Subcutaneous closed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous closed suction drainage